Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

BACKGROUND: Dual inhibition of PI3K and MAPK signaling is conceptually a promising anticancer therapy. OBJECTIVE: This phase 1b trial investigated the safety, maximum tolerated dose (MTD), recommended phase II dose, pharmacokinetics, tumor response, fluorodeoxyglucose positron emission tomography (F...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramanathan, Ramesh K., Von Hoff, Daniel D., Eskens, Ferry, Blumenschein, George, Richards, Donald, Genvresse, Isabelle, Reschke, Susanne, Granvil, Camille, Skubala, Adam, Peña, Carol, Mross, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591420/
https://www.ncbi.nlm.nih.gov/pubmed/32314268
http://dx.doi.org/10.1007/s11523-020-00714-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591420/
https://www.ncbi.nlm.nih.gov/pubmed/32314268
http://dx.doi.org/10.1007/s11523-020-00714-0

Ejemplares similares